Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 6—June 2009
Dispatch

Methicillin-Resistant Staphylococcus aureus USA300 Clone in Long-Term Care Facility

Pierre Tattevin1, Binh An Diep, Michael Jula, and Françoise Perdreau-RemingtonComments to Author 
Author affiliations: Pontchaillou University Hospital, Rennes, France (P. Tattevin); San Francisco General Hospital, San Francisco, California, USA (B.A. Diep, M. Jula, F. Perdreau-Remington)

Main Article

Table

Analysis of MRSA clones obtained in a long-term care facility, San Francisco, California, USA, 1997–2006*

Clonal group Antimicrobial drug resistance, %
Specimen source, %
Ery Cli Cip Sxt Gen Tet SST Respiratory tract Urine Blood†
USA100 (n = 299) 96.2 84.9 95.9 3.3 16.9 2.6 22.7 36.4 35.1 5.8
USA300 (n = 182) 87.8 15.0 79.4 0.6 6.1 13.2 64.3 18.1 10.4 7.1
USA500 (n = 82) 84.7 27.8 71.7 28.2 20.8 6.0 30.5 28 31.7 9.8
LFT (n = 98) 87.3 65.6 62.8 10.9 13.4 7.8 37.2 26.6 26.6 9.6
All MRSA (n = 744) 91.8 64.6 87.0 7.1 21.6 5.1 32.7 25.1 23.1 6.3

*MRSA, methicillin-resistant Staphylococcus aureus; Ery, erythromycin; Cli, clindamycin; Cip, ciprofloxacin; Sxt, trimethoprim-sulfamethozazole; Gen, gentamicin; Tet, tetracycline; SST, skin and skin structure; LFT, low frequency types.
†Blood and other typically sterile sites.

Main Article

1Current affiliation: San Francisco General Hospital, San Francisco, California, USA.

Page created: December 08, 2010
Page updated: December 08, 2010
Page reviewed: December 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external